PD-1 defines a distinct, functional, tissue-adapted state in Vδ1
Journal
Nature cancer
ISSN: 2662-1347
Titre abrégé: Nat Cancer
Pays: England
ID NLM: 101761119
Informations de publication
Date de publication:
03 Jan 2024
03 Jan 2024
Historique:
received:
10
05
2023
accepted:
15
11
2023
medline:
4
1
2024
pubmed:
4
1
2024
entrez:
3
1
2024
Statut:
aheadofprint
Résumé
Checkpoint inhibition (CPI), particularly that targeting the inhibitory coreceptor programmed cell death protein 1 (PD-1), has transformed oncology. Although CPI can derepress cancer (neo)antigen-specific αβ T cells that ordinarily show PD-1-dependent exhaustion, it can also be efficacious against cancers evading αβ T cell recognition. In such settings, γδ T cells have been implicated, but the functional relevance of PD-1 expression by these cells is unclear. Here we demonstrate that intratumoral TRDV1 transcripts (encoding the TCRδ chain of Vδ1
Identifiants
pubmed: 38172341
doi: 10.1038/s43018-023-00690-0
pii: 10.1038/s43018-023-00690-0
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Wellcome Trust (Wellcome)
ID : 220589/Z/20/Z
Organisme : RCUK | Medical Research Council (MRC)
ID : MR/K002627/1
Informations de copyright
© 2024. The Author(s).
Références
Schadendorf, D. et al. Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma. J. Clin. Oncol. 33, 1889–1894 (2015).
pubmed: 25667295
pmcid: 5089162
doi: 10.1200/JCO.2014.56.2736
Wolchok, J. D. et al. Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma. J. Clin. Oncol. 40, 127–137 (2022).
pubmed: 34818112
doi: 10.1200/JCO.21.02229
Long, G. V. et al. Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study. Lancet Oncol. 20, 1083–1097 (2019).
pubmed: 31221619
doi: 10.1016/S1470-2045(19)30274-8
Larkin, J. et al. Five-year survival with combined nivolumab and ipilimumab in advanced melanoma. N. Engl. J. Med. 381, 1535–1546 (2019).
pubmed: 31562797
doi: 10.1056/NEJMoa1910836
Tumeh, P. C. et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568–571 (2014).
pubmed: 25428505
pmcid: 4246418
doi: 10.1038/nature13954
Sade-Feldman, M. et al. Defining T cell states associated with response to checkpoint immunotherapy in melanoma. Cell 175, 998–1013 (2018).
pubmed: 30388456
pmcid: 6641984
doi: 10.1016/j.cell.2018.10.038
Im, S. J. et al. Defining CD8
pubmed: 27501248
pmcid: 5297183
doi: 10.1038/nature19330
Chen, Z. et al. TCF-1-centered transcriptional network drives an effector versus exhausted CD8 T cell-fate decision. Immunity 51, 840–855 (2019).
pubmed: 31606264
pmcid: 6943829
doi: 10.1016/j.immuni.2019.09.013
Eberhardt, C. S. et al. Functional HPV-specific PD-1
pubmed: 34471285
pmcid: 10201342
doi: 10.1038/s41586-021-03862-z
Wu, Y. et al. An innate-like Vδ1
pubmed: 31597756
pmcid: 6877350
doi: 10.1126/scitranslmed.aax9364
Foord, E., Arruda, L. C. M., Gaballa, A., Klynning, C. & Uhlin, M. Characterization of ascites- and tumor-infiltrating γδ T cells reveals distinct repertoires and a beneficial role in ovarian cancer. Sci. Transl. Med. 13, eabb0192 (2021).
pubmed: 33472952
doi: 10.1126/scitranslmed.abb0192
Zakeri, N. et al. Characterisation and induction of tissue-resident gamma delta T-cells to target hepatocellular carcinoma. Nat. Commun. 13, 1372 (2022).
pubmed: 35296658
pmcid: 8927126
doi: 10.1038/s41467-022-29012-1
de Vries, N. L. et al. γδ T cells are effectors of immunotherapy in cancers with HLA class I defects. Nature 613, 743–750 (2023).
pubmed: 36631610
pmcid: 9876799
doi: 10.1038/s41586-022-05593-1
Rancan, C. et al. Exhausted intratumoral Vδ2
pubmed: 36928415
pmcid: 10063448
doi: 10.1038/s41590-023-01448-7
Mensurado, S., Blanco-Domínguez, R. & Silva-Santos, B. The emerging roles of γδ T cells in cancer immunotherapy. Nat. Rev. Clin. Oncol. 20, 178–191 (2023).
pubmed: 36624304
doi: 10.1038/s41571-022-00722-1
Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415–421 (2013).
pubmed: 23945592
pmcid: 3776390
doi: 10.1038/nature12477
McGranahan, N. et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell 171, 1259–1271 (2017).
pubmed: 29107330
pmcid: 5720478
doi: 10.1016/j.cell.2017.10.001
Sade-Feldman, M. et al. Resistance to checkpoint blockade therapy through inactivation of antigen presentation. Nat. Commun. 8, 1136 (2017).
pubmed: 29070816
pmcid: 5656607
doi: 10.1038/s41467-017-01062-w
Rosenthal, R. et al. Neoantigen-directed immune escape in lung cancer evolution. Nature 567, 479–485 (2019).
pubmed: 30894752
pmcid: 6954100
doi: 10.1038/s41586-019-1032-7
Wu, Y., Biswas, D. & Swanton, C. Impact of cancer evolution on immune surveillance and checkpoint inhibitor response. Semin. Cancer Biol. 84, 89–102 (2022).
pubmed: 33631295
pmcid: 9253787
doi: 10.1016/j.semcancer.2021.02.013
Dijkstra, K. K., Wu, Y. & Swanton, C. The effects of clonal heterogeneity on cancer immunosurveillance. Annu. Rev. Cancer Biol. 7, 131–147 (2023).
doi: 10.1146/annurev-cancerbio-061521-101910
Gentles, A. J. et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat. Med. 21, 938–945 (2015).
pubmed: 26193342
pmcid: 4852857
doi: 10.1038/nm.3909
Wu, Y. et al. A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer. Nat. Cancer 3, 696–709 (2022).
pubmed: 35637401
pmcid: 9236901
doi: 10.1038/s43018-022-00376-z
Zlatareva, I. & Wu, Y. Local γδ T cells: translating promise to practice in cancer immunotherapy. Br. J. Cancer 129, 393–405 (2023).
pubmed: 37311978
pmcid: 10403623
doi: 10.1038/s41416-023-02303-0
Sharpe, A. H. & Pauken, K. E. The diverse functions of the PD1 inhibitory pathway. Nat. Rev. Immunol. 18, 153–167 (2018).
pubmed: 28990585
doi: 10.1038/nri.2017.108
Hodi, F. S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711–723 (2010).
pubmed: 20525992
pmcid: 3549297
doi: 10.1056/NEJMoa1003466
Holtmeier, W. et al. The TCR δ repertoire in normal human skin is restricted and distinct from the TCR δ repertoire in the peripheral blood. J. Invest. Dermatol. 116, 275–280 (2001).
pubmed: 11180004
doi: 10.1046/j.1523-1747.2001.01250.x
Ebert, L. M., Meuter, S. & Moser, B. Homing and function of human skin γδ T cells and NK cells: relevance for tumor surveillance. J. Immunol. 176, 4331–4336 (2006).
pubmed: 16547270
doi: 10.4049/jimmunol.176.7.4331
Toulon, A. et al. A role for human skin-resident T cells in wound healing. J. Exp. Med. 206, 743–750 (2009).
pubmed: 19307328
pmcid: 2715110
doi: 10.1084/jem.20081787
Hugo, W. et al. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell 165, 35–44 (2016).
pubmed: 26997480
pmcid: 4808437
doi: 10.1016/j.cell.2016.02.065
Riaz, N. et al. Tumor and microenvironment evolution during immunotherapy with nivolumab. Cell 171, 934–949 (2017).
pubmed: 29033130
pmcid: 5685550
doi: 10.1016/j.cell.2017.09.028
Auslander, N. et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma. Nat. Med. 24, 1545–1549 (2018).
pubmed: 30127394
pmcid: 6693632
doi: 10.1038/s41591-018-0157-9
Liu, D. et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma. Nat. Med. 25, 1916–1927 (2019).
pubmed: 31792460
pmcid: 6898788
doi: 10.1038/s41591-019-0654-5
Du, K. et al. Pathway signatures derived from on-treatment tumor specimens predict response to anti-PD1 blockade in metastatic melanoma. Nat. Commun. 12, 6023 (2021).
pubmed: 34654806
pmcid: 8519947
doi: 10.1038/s41467-021-26299-4
Kovács, S. A. & Győrffy, B. Transcriptomic datasets of cancer patients treated with immune-checkpoint inhibitors: a systematic review. J. Transl. Med. 20, 249 (2022).
pubmed: 35641998
pmcid: 9153191
doi: 10.1186/s12967-022-03409-4
Harmon, C. et al. γδ T cell dichotomy with opposing cytotoxic and wound healing functions in human solid tumors. Nat. Cancer 4, 1122–1137 (2023).
pubmed: 37474835
doi: 10.1038/s43018-023-00589-w
Hayday, A. C. Paul’s Fundamental Immunology (Lippincott Williams & Wilkins, 2022).
Clark, R. A. et al. The vast majority of CLA
pubmed: 16547281
doi: 10.4049/jimmunol.176.7.4431
Kornberg, A. et al. Gluten induces rapid reprogramming of natural memory αβ and γδ intraepithelial T cells to induce cytotoxicity in celiac disease. Sci. Immunol. 8, eadf4312 (2023).
pubmed: 37450575
pmcid: 10481382
doi: 10.1126/sciimmunol.adf4312
Savas, P. et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat. Med. 24, 986–993 (2018).
pubmed: 29942092
doi: 10.1038/s41591-018-0078-7
Menares, E. et al. Tissue-resident memory CD8
pubmed: 31562311
pmcid: 6765014
doi: 10.1038/s41467-019-12319-x
Okła, K., Farber, D. L. & Zou, W. Tissue-resident memory T cells in tumor immunity and immunotherapy. J. Exp. Med. 218, e20201605 (2021).
pubmed: 33755718
pmcid: 7992502
doi: 10.1084/jem.20201605
Kumar, B. V. et al. Human tissue-resident memory T cells are defined by core transcriptional and functional signatures in lymphoid and mucosal sites. Cell Rep. 20, 2921–2934 (2017).
pubmed: 28930685
pmcid: 5646692
doi: 10.1016/j.celrep.2017.08.078
Mackay, L. K. et al. Hobit and Blimp1 instruct a universal transcriptional program of tissue residency in lymphocytes. Science 352, 459–463 (2016).
pubmed: 27102484
doi: 10.1126/science.aad2035
Shin, H. et al. A role for the transcriptional repressor Blimp-1 in CD8
pubmed: 19664943
pmcid: 2747257
doi: 10.1016/j.immuni.2009.06.019
Hwang, S., Cobb, D. A., Bhadra, R., Youngblood, B. & Khan, I. A. Blimp-1-mediated CD4 T cell exhaustion causes CD8 T cell dysfunction during chronic toxoplasmosis. J. Exp. Med. 213, 1799–1818 (2016).
pubmed: 27481131
pmcid: 4995081
doi: 10.1084/jem.20151995
Yoshikawa, T. et al. Genetic ablation of PRDM1 in antitumor T cells enhances therapeutic efficacy of adoptive immunotherapy. Blood 139, 2156–2172 (2022).
pubmed: 34861037
doi: 10.1182/blood.2021012714
Parga-Vidal, L. et al. Hobit identifies tissue-resident memory T cell precursors that are regulated by Eomes. Sci. Immunol. 6, eabg3533 (2021).
pubmed: 34417257
doi: 10.1126/sciimmunol.abg3533
Kitakaze, M. et al. Cancer-specific tissue-resident memory T-cells express ZNF683 in colorectal cancer. Br. J. Cancer 128, 1828–1837 (2023).
pubmed: 36869093
pmcid: 10147592
doi: 10.1038/s41416-023-02202-4
Parry, E. M. et al. ZNF683 marks a CD8
pubmed: 37738974
doi: 10.1016/j.ccell.2023.08.013
Blank, C. U. et al. Defining ‘T cell exhaustion’. Nat. Rev. Immunol. 19, 665–674 (2019).
pubmed: 31570879
pmcid: 7286441
doi: 10.1038/s41577-019-0221-9
Wu, T. et al. The TCF1–Bcl6 axis counteracts type I interferon to repress exhaustion and maintain T cell stemness. Sci. Immunol. 1, eaai8593 (2016).
pubmed: 28018990
pmcid: 5179228
doi: 10.1126/sciimmunol.aai8593
Man, K. et al. Transcription factor IRF4 promotes CD8
pubmed: 29246443
doi: 10.1016/j.immuni.2017.11.021
Jadhav, R. R. et al. Epigenetic signature of PD-1
pubmed: 31227606
pmcid: 6628832
doi: 10.1073/pnas.1903520116
Day, C. L. et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443, 350–354 (2006).
pubmed: 16921384
doi: 10.1038/nature05115
Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687 (2005).
pubmed: 16382236
doi: 10.1038/nature04444
Gao, J. et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167, 397–404 (2016).
pubmed: 27667683
pmcid: 5088716
doi: 10.1016/j.cell.2016.08.069
Rooney, M. S., Shukla, S. A., Wu, C. J., Getz, G. & Hacohen, N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 160, 48–61 (2015).
pubmed: 25594174
pmcid: 4856474
doi: 10.1016/j.cell.2014.12.033
Cózar, B. et al. Tumor-infiltrating natural killer cells. Cancer Discov. 11, 34–44 (2021).
pubmed: 33277307
doi: 10.1158/2159-8290.CD-20-0655
Almeida, A. R. et al. Delta one T cells for immunotherapy of chronic lymphocytic leukemia: clinical-grade expansion/differentiation and preclinical proof of concept. Clin. Cancer Res. 22, 5795–5804 (2016).
pubmed: 27307596
doi: 10.1158/1078-0432.CCR-16-0597
Tan, L. et al. A fetal wave of human type 3 effector γδ cells with restricted TCR diversity persists into adulthood. Sci. Immunol. 6, eabf0125 (2021).
pubmed: 33893173
doi: 10.1126/sciimmunol.abf0125
Reck, M. et al. Pembrolizumab versus chemotherapy for PD-L1–positive non-small-cell lung cancer. N. Engl. J. Med. 375, 1823–1833 (2016).
pubmed: 27718847
doi: 10.1056/NEJMoa1606774
Ansell, S. M. et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N. Engl. J. Med. 372, 311–319 (2015).
pubmed: 25482239
doi: 10.1056/NEJMoa1411087
Bortolomeazzi, M. et al. Immunogenomics of colorectal cancer response to checkpoint blockade: analysis of the KEYNOTE 177 trial and validation cohorts. Gastroenterology 161, 1179–1193 (2021).
pubmed: 34197832
doi: 10.1053/j.gastro.2021.06.064
McKenzie, D. R. et al. Normality sensing licenses local T cells for innate-like tissue surveillance. Nat. Immunol. 23, 411–422 (2022).
pubmed: 35165446
pmcid: 8901436
doi: 10.1038/s41590-021-01124-8
Mueller, S. N. & Mackay, L. K. Tissue-resident memory T cells: local specialists in immune defence. Nat. Rev. Immunol. 16, 79–89 (2016).
pubmed: 26688350
doi: 10.1038/nri.2015.3
McVay, L. D., Jaswal, S. S., Kennedy, C., Hayday, A. & Carding, S. R. The generation of human γδ T cell repertoires during fetal development. J. Immunol. 160, 5851–5860 (1998).
pubmed: 9637496
doi: 10.4049/jimmunol.160.12.5851
Carding, S. R. & Egan, P. J. γδ T cells: functional plasticity and heterogeneity. Nat. Rev. Immunol. 2, 336–345 (2002).
pubmed: 12033739
doi: 10.1038/nri797
Prasad, V. & Addeo, A. The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No. Ann. Oncol. 31, 1112–1114 (2020).
pubmed: 32771305
doi: 10.1016/j.annonc.2020.07.001
Gordon, S. R. et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature 545, 495–499 (2017).
pubmed: 28514441
pmcid: 5931375
doi: 10.1038/nature22396
Hsu, J. et al. Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade. J. Clin. Invest. 128, 4654–4668 (2018).
pubmed: 30198904
pmcid: 6159991
doi: 10.1172/JCI99317
DeRenzo, C. & Gottschalk, S. Genetic modification strategies to enhance CAR T cell persistence for patients with solid tumors. Front. Immunol. 10, 218 (2019).
pubmed: 30828333
pmcid: 6384227
doi: 10.3389/fimmu.2019.00218
Donnadieu, E., Dupré, L., Pinho, L. G. & Cotta‐de‐Almeida, V. Surmounting the obstacles that impede effective CAR T cell trafficking to solid tumors. J. Leukoc. Biol. 108, 1067–1079 (2020).
pubmed: 32620049
doi: 10.1002/JLB.1MR0520-746R
Melenhorst, J. J. et al. Decade-long leukaemia remissions with persistence of CD4
pubmed: 35110735
pmcid: 9166916
doi: 10.1038/s41586-021-04390-6
Salimi, M. et al. Enhanced isolation of lymphoid cells from human skin. Clin. Exp. Dermatol. 41, 552–556 (2016).
pubmed: 26805629
pmcid: 4981906
doi: 10.1111/ced.12802
Clark, R. A. et al. A novel method for the isolation of skin resident T cells from normal and diseased human skin. J. Invest. Dermatol. 126, 1059–1070 (2006).
pubmed: 16484986
doi: 10.1038/sj.jid.5700199